Cancer Vaccine + Sargramostim for Breast Cancer or alternatively, Cancer Vaccine + Sargramostim for Ovarian Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new treatment for advanced breast and ovarian cancer. The treatment helps the body's defense system recognize and attack cancer cells, while another component increases the number of defense cells. Researchers aim to find the safest dose and see if it effectively triggers the body's defense system. This type of treatment has shown promise in previous studies for its safety and ability to stimulate the body's defense system.
Research Team
Mary L. Disis
Principal Investigator
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Eligibility Criteria
This trial is for adults with stage III-IV breast or ovarian cancer that overexpresses HER2 and are in remission. They must have normal heart, kidney, liver function, blood counts within specific ranges, and no ability to bear children. Excluded are those with autoimmune diseases, active infections like HIV, severe heart or lung conditions, or on other treatment studies.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- pNGVL3-hICD vaccine
- Sargramostim
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
National Cancer Institute (NCI)
Collaborator